Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Sees Unusually-High Trading Volume - What's Next?

Key Points

• Fresenius Medical Care’s trading volume surged 81% to approximately 1.25 million shares, while the stock fell to $21.02 from a prior close of $22.42.
• Analyst sentiment remains cautious: seven analysts rate the stock a Hold and five rate it a Sell, producing an overall “Reduce” rating and a consensus price target of $23.67.
• The company exceeded quarterly expectations, reporting EPS of $0.66 versus $0.62 expected and revenue of $5.55 billion versus $5.48 billion forecast; institutional investors collectively own 8.37% of the stock.

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) saw unusually-strong trading volume on Wednesday. Approximately 1,247,992 shares changed hands during trading, an increase of 81% from the previous session's volume of 688,695 shares. The stock last traded at $21.0190 and had previously closed at $22.42.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Weiss Ratings reissued a "hold (c)" rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, August 4th. Sanford C. Bernstein increased their price objective on shares of Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the company a "market perform" rating in a research report on Thursday, August 6th. Truist Financial set a $25.00 target price on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, August 5th. Citigroup reaffirmed a "neutral" rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 17th. Finally, Zacks Research raised Fresenius Medical Care AG & Co. KGaA from a "strong sell" rating to a "hold" rating in a research note on Monday, July 6th. Seven investment analysts have rated the stock with a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA presently has an average rating of "Reduce" and a consensus target price of $23.67.

Fresenius Medical Care AG & Co. KGaA Price Performance

The company has a debt-to-equity ratio of 0.43, a current ratio of 1.07 and a quick ratio of 0.75. The firm has a market cap of $11.17 billion, a P/E ratio of 10.78, a PEG ratio of 4.12 and a beta of 0.74. The stock's 50-day simple moving average is $23.20 and its two-hundred day simple moving average is $22.93.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last released its earnings results on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.83% and a return on equity of 9.28%. The firm had revenue of $5.55 billion during the quarter, compared to analyst estimates of $5.48 billion. Equities research analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 2.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Pzena Investment Management LLC raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 2.0% in the first quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company's stock worth $339,592,000 after buying an additional 299,986 shares during the period. Moran Wealth Management LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 31.5% in the first quarter. Moran Wealth Management LLC now owns 347,773 shares of the company's stock worth $7,846,000 after purchasing an additional 83,311 shares during the period. Quantinno Capital Management LP lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 15.7% during the first quarter. Quantinno Capital Management LP now owns 341,343 shares of the company's stock worth $7,701,000 after purchasing an additional 46,428 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 479.2% during the first quarter. Royal Bank of Canada now owns 216,861 shares of the company's stock valued at $4,893,000 after purchasing an additional 179,418 shares during the period. Finally, Assetmark Inc. grew its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 190.7% in the first quarter. Assetmark Inc. now owns 132,320 shares of the company's stock worth $2,985,000 after purchasing an additional 86,798 shares during the last quarter. Hedge funds and other institutional investors own 8.37% of the company's stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney disease and kidney failure. The company provides dialysis care through a global network of outpatient clinics and supports patients with related medical services, including vascular access care, laboratory services and care coordination.

In addition to operating dialysis facilities, Fresenius Medical Care develops and manufactures products used in dialysis treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.